Aspergillosis is described in the packet definition as an infection, growth or allergic response caused by the Aspergillus fungus. The definition names several kinds: allergic bronchopulmonary aspergillosis (ABPA), in which the fungus causes allergic respiratory symptoms similar to asthma without invading tissue; invasive aspergillosis, which usually affects people with weakened immune systems, damages tissues, most commonly in the lungs, and can also involve other organs such as the kidneys and brain; and aspergilloma, a fungus ball that develops in an area of previous lung disease. Prevalence is listed as unknown in this packet.

The packet provides no phenotype list, so no symptom frequencies are certified. The definition describes wheezing and coughing as allergic respiratory symptoms similar to asthma in ABPA, and describes tissue invasion and damage in invasive disease. Age of onset is not certified in this packet.

Per the packet definition, the condition is caused by the Aspergillus fungus. Invasive disease usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. Aspergilloma develops in an area of previous lung disease such as tuberculosis or lung abscess. The packet lists no associated genes and no inheritance pattern.

The packet does not certify diagnostic methods or diagnostic criteria for aspergillosis.

The packet certifies no foundational therapies or management guidance. Its FDA records list three products with ACTIVE market status, each approved through an NDA reviewed by the Center for Drug Evaluation and Research: TOLSURA (itraconazole; approval date 2018-12-11), SPORANOX (itraconazole; 1992-09-11) and prednisolone sodium phosphate (1986-05-28). The packet does not state indications, populations, doses or schedules for these products.

Prognosis is not certified in this packet. The only natural history statement available is the definition's description that an aspergilloma gradually enlarges, destroying lung tissue, and usually does not spread to other areas.

The packet lists ClinicalTrials.gov records for aspergillosis. These include NCT07825259 (itraconazole and posaconazole for chronic pulmonary aspergillosis; phase 3; not yet recruiting; Post Graduate Institute of Medical Education and Research; 2026-11-01 to 2029-12-31), NCT06447402 (nebulized amphotericin B versus nebulized normal saline as maintenance; phase 3; recruiting; same sponsor; 2024-06-03 to 2027-08-31) and NCT06794554 (rezafungin for chronic pulmonary aspergillosis in adults; phase 2; active not recruiting; Mundipharma Research Limited; 2025-06-30 to 2026-12-30). A trial title is not a claim about an intervention's effect.